Akston Biosciences Corporation

15 articles about Akston Biosciences Corporation

• Akston Biosciences Receives 2023 Most Innovative Award at Animal Health Summit

  8/31/2023

  Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, received the 2023 Innovation Award at the just-concluded Animal Health Summit in Kansas City, MO.

• Akston Biosciences CEO to Present at the 2023 Animal Health Summit in Kansas City

  8/28/2023

  Akston Biosciences Corporation, which invents, develops and manufactures breakthrough protein therapeutics for Companion Animal Health, announced that President & CEO Todd Zion, Ph.D., will present at the 2023 Animal Health Summit in Kansas City, MO on August 28, 2023.

• 

  Clinical Catch-Up: xBiotech, Exelixis, DermBiont Target Cancer

  6/27/2022

  While it was a relatively quiet week for clinical trial announcements overall, BioSpace takes a look at some of the more intriguing ones. 

• Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

  6/24/2022

  Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine.

• Akston Biosciences Doses First Participants in Phase II Clinical Trial for Shelf-Stable COVID-19 Booster

  5/12/2022

  Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it dosed the first set of volunteers in an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.

• Akston Biosciences CEO to Present at the World Vaccine Congress - Apr 12, 2022

  4/12/2022

  Akston Biosciences Corporation, a developer of new classes of biologics, announced that its president and CEO, Todd Zion, Ph.D., has been invited to present at this year’s World Vaccine Congress.

• Akston Biosciences Receives Regulatory Approval for Phase II Clinical Trial for Shelf-Stable COVID-19 Vaccine Booster

  3/31/2022

  Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced today it received regulatory approval in the Netherlands to conduct an open-label study of AKS-452, its protein subunit COVID-19 vaccine, as a booster.

• Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries

  3/17/2022

  Akston Biosciences and Biolexis Collaborate to Launch a Room Temperature Stable 2nd Generation COVID-19 Vaccine in 130+ Countries.

• Akston Biosciences Announces Publication in Vaccine of Positive Data for a Room Temperature Protein Subunit COVID-19 Vaccine

  2/8/2022

  Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced publication of positive results from a 60-subject, open-label, Phase I trial of AKS-452, its shelf stable protein subunit COVID-19 vaccine candidate.

• Akston Biosciences Announces Positive Top-Line Data From Phase II Study of COVID-19 Vaccine in the Netherlands

  12/22/2021

  Akston Biosciences, Inc. a developer of new classes of biologic therapeutics, announced positive data from the Phase II clinical trial of its second-generation SARS-CoV2 vaccine candidate, AKS-452.

• Akston Biosciences Doses First Subjects in Phase II Clinical Trial in India of Second-Generation COVID-19 Vaccine

  11/20/2021

  Akston Biosciences Corporation, a developer of new classes of biologic therapeutics, announced that the first of 100 subjects were dosed in an open-label bridging study of AKS-452, its protein subunit COVID-19 vaccine candidate, in India.

• Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale

  7/21/2021

  Akston Biosciences Corporation today announced a commercial agreement with Seppic S.A., a supplier of specialty healthcare ingredients, for the supply of adjuvant for use in Akston’s COVID-19 Fc fusion protein vaccine candidate, AKS-452.

• Akston Biosciences Announces Positive Phase I Data for Second-Generation COVID-19 Vaccine Candidate

  7/8/2021

  Today, Akston Biosciences Corporation , a developer of new classes of biologic therapeutics announced positive results from a 60-subject, open-label, Phase I trial of AKS-452, its protein subunit, room temperature stable, COVID-19 vaccine candidate.

• Akston Biosciences Launches Phase I/II Clinical Trial of Second-Generation COVID-19 Vaccine

  4/12/2021

  First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial Vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit) 176 volunteers will participate in the clinical trial

• Helmsley Charitable Trust And Akston Biosciences Announce Partnership To Advance Novel Technology To Treat Type 1 Diabetes

  3/16/2017